Please login to the form below

Not currently logged in
Email:
Password:

Dr Desiree Luthman joins Verona Pharma

She takes up its vice president position

Desiree LuthmanUK-based clinical stage biopharma company Verona Pharma has appointed Dr Desiree Luthman as its vice president of regulatory affairs.

Luthman’s expertise lies in a series of roles leading regulatory affairs teams and strategies for pharmaceutical products spanning from early development to post-approval marketing.

She has also held various regulatory positions for global pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene and AstraZeneca.

Jan-Anders Karlsson, chief executive officer of Verona Pharma, said: “We welcome Desiree to our growing pharma team.

“She has an accomplished track record of working closely with the FDA and EMA on behalf of international healthcare companies to achieve key regulatory milestones.

“Her vast experience will be instrumental as we advance our regulatory plans in the US and Europe under her leadership in our effort to deliver important new therapies to patients with respiratory diseases.”

Prior to her new role in Verona Pharma, Luthman previously directed regulatory activities related to pulmonary disease at Sanofi and led its regulatory team through the FDA approval of dupilumab for atopic dermatitis in the US.

27th June 2017

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics